Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Categories Side Effects

21 through 30 of 35

Relevance: High

Research Timeline: Post Approval

Guideline : Expert guidelines on COVID-19 vaccines and timing of breast screening tests

Relevance: High

Research Timeline: Post Approval

Most relevant for: People considering screening mammography after getting a COVID-19 vaccine.

COVID-19 vaccines work by helping the immune system destroy the virus. Lymph nodes are an important part of the immune system. COVID-19 vaccines may cause temporary swelling in some lymph nodes, which may look suspicious on a mammogram.  The Society for Breast Imaging and other professional organizations have released recommendations for the timing of mammograms after COVID-19 vaccines.  (3/30/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : How breast cancer patients experience hormone therapy

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Breast cancer patients taking or considering taking hormone therapy

Side effects from hormone therapy are a common reason that many men and women with hormone receptor-positive breast cancer stop treatment early. Some people never start hormone therapy. This study asked patients about their experiences with hormone (or endocrine) therapy. The results suggest that there may be ways to improve the number of patients who stick with therapy. Patients need better ways to manage hormone therapy-related side effects. (1/19/21)

Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Personal Story : Coping with chemotherapy-induced hair loss

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People who receive chemotherapy for cancer treatment

Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : FDA issues alert on a drug combination to treat triple-negative breast cancer

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic triple-negative breast cancer

The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)

Read More

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : FDA issues warning on CDK inhibitors

Relevance: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People currently taking a CDK inhibitor

The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)

Read More

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : FDA asks Allergan to recall certain textured breast implants

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with, or considering breast reconstruction with implants

On July 25, 2019, the Food and Drug Administration requested that breast implant manufacturer Allergan recall its BIOCELL textured implants and expanders due to an association with a rare type of lymphoma called Breast Implant Associated Anaplastic Large Cell Lymphoma or BIA-ALCL. The FDA does not recommend removing implants for people who do not have disease symptoms. This XRAYS review updates information about this FDA recall. (7/29/19)

Read More

Relevance: Medium-Low

Strength of Science: Low

Research Timeline: Post Approval

View Related Clinical Trials

Study : Breast cancer implant study suggests links with illness but has serious flaws

Relevance: Medium-Low

Strength of Science: Low

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women with or considering breast implant reconstruction

THIS INFORMATION HAS BEEN UPDATED: In October 2021, the FDA issued guidance for people with breast implants Read our latest review on this topic.  

An article in the Annals of Surgery, researchers conclude that their work supports an association between silicone breast implants and a range of conditions. This journal article was accompanied by two editorials in which experts voiced their disagreement with the way the analysis was performed and the conclusions of the authors. (2/21/19)

Read More

Relevance: Medium-High

View Related Clinical Trials

Guideline : American Heart Association examines the challenges of cardiovascular disease and breast cancer

Relevance: Medium-High

View Related Clinical Trials

Most relevant for: People diagnosed with breast cancer

Current breast cancer treatments can negatively affect cardiovascular health.  Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer.  This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)

Read More

Relevance: Medium

Quality of Writing: High

Research Timeline: Human Research

View Related Clinical Trials

Article : The buzz around MonaLisa Touch

Relevance: Medium

Quality of Writing: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women experiencing vaginal symptoms from menopause

THIS INFORMATION HAS BEEN UPDATED. The FDA issued an alert in July, 2018 noting that laser or radiofrequency devices that have received FDA clearance are ONLY cleared for treating abnormal or pre-cancerous cervical or vaginal tissue and genital warts and have NOT been approved for vaginal rejuvenation. There are currently clinical trials enrolling women to study whether laser and radiofrequency devices can improve vaginal atrophy and other menopausal symptoms. 

For many young breast cancer survivors and high-risk women, the side effects from early menopause after treatment and surgery can negatively impact their personal lives. This XRAYS looks at one of the many recent media articles on a laser procedure called MonaLisa Touch. The article, "Is Laser Treatment for Vaginal Atrophy Safe?"  was published online in 2017 by FOX News and written by Dr. Manny Alvarez. XRAYS will discuss what this laser procedure actually is and how it may impact a young breast cancer patient’s life after treatment. (1/19/18)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Does scalp cooling help prevent hair loss after chemotherapy?

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Patient undergoing chemotherapy

Hair loss is one of the most recognized and distressing side effects of some chemotherapies. Two studies looked at the use of scalp cooling therapy to help reduce hair loss after chemotherapy for early-stage breast cancer. (5/15/17) 

Update: Based on data from clinical trials, the FDA approved Dignicap scalp cooling device for treatment in patients diagnosed with solid tumors who are receiving chemotherapy. 

Read More